Fig. 6: FimH functions as a mucosal adjuvant for the inhibition of lung metastasis of melanoma.

C57BL/6 mice were injected intranasally (i.n.) with 2.5 mg per kg of FimH or 1 mg per kg of LPS. a The mean fluorescence intensity (MFI) levels of costimulatory molecules and MHC classes I and II in the mediastinal-LN (mLN) DCs are shown 24 h after treatment. (n = 6 mice, one-way ANOVA, mean ± SEM). b Transferred OT-I and OT-II cell proliferation was measured by flow cytometry. c–e C57BL/6 mice were injected intravenously (i.v.) with 1 × 10⁶ B16 melanoma cells and treated i.n. with PBS and 2.5 mg per kg of TRP2, 2.5 mg per kg of FimH, or a combination of TRP2 and FimH after 5 and 10 days of the tumor-cell injections. c Metastatic B16 tumor cells in the lungs after 14 days of the tumor-cell injection (left panel) and number of surface tumor nodules are shown (right panel). (n = 6 mice, one-way ANOVA, mean ± SEM). d H&E stained lung sections (left panel) and numbers of metastatic lesions in the lung (right panel) after 14 days of tumor-cell injection are shown. e TRP2-specific IFN-γ production in the mLN cells was analyzed by ELISpot analysis. (n = 6 mice, one-way ANOVA, mean ± SEM).